Base to Base Biotech
Base to Base Biotech
Podcast Description
The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world.Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.Base to Base is an Ayr Coastal Media Ltd production.
Podcast Insights
Content Themes
The podcast covers a range of topics within the biotech realm, including new drug developments, technological advancements, clinical trial results, and product launches. Specific episodes highlight innovations like non-addictive pain alternatives and wearable devices for bone health, alongside discussions on artificial intelligence in disease diagnostics and cancer immunotherapy strategies. Each episode aims to keep listeners informed and engaged with the dynamic biotech sector.
The Base to Base Biotech podcast is a weekly look at what’s happening in the world of biotech, with interviews with biotech leaders around the world.
Whether it’s a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.
The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.
Base to Base is an Ayr Coastal Media Ltd production.
This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders.
Renexxion
Renexxion, Inc. is a privately held US-headquartered clinical-stage biopharmaceutical company, with a subsidiary in Ireland, committed to developing new therapies for patients with gastrointestinal disorders.
Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract.
Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion recently announced positive results from MOVE-IT, a global phase 2b, randomised placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.